Monte Rosa Therapeutics, Inc. (GLUE)

$9.27

+0.27 (+3.00%)
Rating:
Recommendation:
-
Symbol GLUE
Price $9.27
Beta 0.000
Volume Avg. 0.19M
Market Cap 432.616M
Shares () -
52 Week Range 6.05-45.56
1y Target Est -
DCF Unlevered GLUE DCF ->
DCF Levered GLUE LDCF ->
ROE -24.47% Sell
ROA -24.74% Sell
Operating Margin -
Debt / Equity 6.18% Neutral
P/E -
P/B 1.33 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest GLUE news


Dr. Markus Warmuth M.D.
Healthcare
Biotechnology
NASDAQ Global Select

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.